Sugi Predict

Sugi Predict / Targets / MECP2

MECP2

Methyl-CpG-binding protein 2 · P51608 · MECP2 on Sugi Atlas →

2,691 patent compounds predicted against MECP2, 2,087 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6267593 SCHEMBL6267593 1.00 3/20
SCHEMBL6274373 SCHEMBL6274373 0.72 3/20
SCHEMBL6265429 SCHEMBL6265429 0.65 3/20
SCHEMBL6266559 SCHEMBL6266559 0.64 3/20
SCHEMBL6277272 SCHEMBL6277272 0.60 3/20
SCHEMBL6274213 SCHEMBL6274213 0.55 3/20
SCHEMBL2107839 SCHEMBL2107839 0.54 3/20
SCHEMBL6274214 SCHEMBL6274214 0.52 3/20
SCHEMBL6277474 SCHEMBL6277474 0.47 3/20
SCHEMBL6278966 SCHEMBL6278966 0.42 2/20
SCHEMBL6274998 SCHEMBL6274998 0.39 2/20
SCHEMBL1924513 SCHEMBL1924513 0.34 2/20
SCHEMBL653811 SCHEMBL653811 1.00 1/20
SCHEMBL5155715 SCHEMBL5155715 1.00 1/20
SCHEMBL3422962 SCHEMBL3422962 0.89 1/20
SCHEMBL1142913 SCHEMBL1142913 0.83 1/20
SCHEMBL7678939 SCHEMBL7678939 0.81 1/20
Bromide Bromide (SCHEMBL7673197) 0.79 1/20
SCHEMBL7552748 SCHEMBL7552748 0.77 1/20
Bromide Bromide (SCHEMBL7669000) 0.75 1/20

Clinical trials — most relevant to MECP2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome PHASE3UNKNOWN
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome PHASE3RECRUITING
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) PHASE3RECRUITING
Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome PHASE1/PHASE2COMPLETED
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) PHASE2COMPLETED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
An Open-Label Trial of Donepezil in Fragile X Syndrome PHASE1COMPLETED
Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome EARLY_PHASE1ACTIVE_NOT_RECRUITING
Patients With RETT Syndrome nanUNKNOWN
Rett Syndrome Registry nanRECRUITING
Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Biotics_RTT) nanCOMPLETED
Natural History of Rett Syndrome & Related Disorders nanCOMPLETED
Biobanking of Rett Syndrome and Related Disorders nanCOMPLETED
Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe) nanCOMPLETED
Metabolic Evaluation of Nutrition in Rett Syndrome nanCOMPLETED
Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X Syndrome nanUNKNOWN
Osteoporosis in RETT Syndrome nanCOMPLETED
Analysis of the Glutathione Cycle in Children With Rett Syndrome nanWITHDRAWN
The Diagnostic Experience of Male Rett Syndrome nanUNKNOWN
GCB-002 in Treatment of Patients With Rett Syndrome nanENROLLING_BY_INVITATION
Family Resilience Initiative Research Program nanUNKNOWN
Epigenetics and Protective Factors in the Preterm Infant nanUNKNOWN
Emotional Regulation in Children With ND: the Role of Genomic Variation, Proteomic Patterns, and Early Experience nanUNKNOWN
Development of the ORCA Communication Measure for Rett Syndrome nanCOMPLETED
Gene Editing as a Therapeutic Approach for Rett Syndrome nanRECRUITING
Rare Diseases Clinical Research Network: Neurophysiological Correlates nanCOMPLETED
Creatine Metabolism in Rett Syndrome nanCOMPLETED
The Rett Syndrome Global Registry nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MECP2 binder may also engage these)

ProteinNameSimilarity
Q95LG8 — 1.000 Q95LG8 →
Q9Z2D6 — 1.000 Q9Z2D6 →
Q00566 — 1.000 Q00566 →
Q9WU42 — 0.982 Q9WU42 →
NCOR2 Nuclear receptor corepressor 2 0.979 landscape →
Q96N64 — 0.977 Q96N64 →
Q69Z61 — 0.974 Q69Z61 →
BRD8 Bromodomain-containing protein 8 0.973 landscape →
Q9UGU5 — 0.971 Q9UGU5 →
A0JPQ7 — 0.971 A0JPQ7 →
Q62511 — 0.971 Q62511 →
ZFP91 E3 ubiquitin-protein ligase ZFP91 0.970 landscape →
MBD2 Methyl-CpG-binding domain protein 2 0.970 landscape →
Q9Z2E1 — 0.970 Q9Z2E1 →
F7AQ22 — 0.970 F7AQ22 →
Q8N9M1 — 0.969 Q8N9M1 →
Q5T6C5 — 0.968 Q5T6C5 →
Q6NXK2 — 0.968 Q6NXK2 →
Q8K2W6 — 0.968 Q8K2W6 →
A0A1L8GR68 — 0.967 A0A1L8GR68 →
A4FV61 — 0.967 A4FV61 →
Q9HCE3 — 0.967 Q9HCE3 →
P12755 — 0.966 P12755 →
P49797 — 0.965 P49797 →
Q9WTU0 — 0.965 Q9WTU0 →
Q8BVA4 — 0.965 Q8BVA4 →
Q60974 — 0.964 Q60974 →
Q8R3Y5 — 0.964 Q8R3Y5 →
O00287 — 0.964 O00287 →
Q8N228 — 0.964 Q8N228 →